|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients显示文摘AIM: To analyze the correlation between cytokineinduced killer (CIK) cells adoptive immunotherapy and cancer-related death in gastric cancer patients. METHODS: One hundred and fifty-six gastric cancer patients after operation at the Third Affiliated Hospital of Soochow University were enrolled in this study. Their clinical data including demographic characteristics, operation time, tumor size, pathological type and staging, tumor metastasis, outcome of chemotherapy or CIK cells adoptive immunotherapy, survival time or time of death were collected with a standard structured questionnaire. Kaplan-Meier method was used to estimate the median survival time, and the 2- and 5- year survival rates. Hazard risk (HR) and 95% confidence interval (95% CI) of CIK cells adoptive immunotherapy for gastric cancer were calculated using the two-stage time-dependent covariates Cox model. RESULTS: The survival time of gastric cancer patients was longer after CIK cells adoptive immunotherapy than after chemotherapy (χ 2 = 10.907, P = 0.001). The median survival time of gastric cancer patients was also longer after CIK cells adoptive immunotherapy than after chemotherapy (49 mo vs 27 mo, P < 0.05). The 2- and 5-year survival rates of gastric cancer patients were significantly higher after CIK cells adoptive immunotherapy than after chemotherapy (73.5% vs 52.6%, 40.4% vs 23.9%, P < 0.05). A significant difference was observed in the survival curve for patients who received CIK cells adoptive immunotherapy (0, 1-10, 11-25, and over 25 frequencies) (χ 2 = 14.534, P = 0.002). The frequencies of CIK cells adoptive immunotherapy were significantly related with the decreasing risk of death in gastric cancer patients after adjustment for sex and age of the patients, tumor stage and relapse (HR = 0.54, 95% CI: 0.36-0.80) when the first stage Cox model was used to define the subjects who remained alive beyond 36 mo as survivors. However, no correlation was observed between the frequencies of death in CIK cells adoptive immunotherapy and the risk of gastric cancer patients (HR = 1.09, 95% CI: 0.63-0.89) when the second stage Cox model was used to define the subjects who survived for more than 36 mo as survivors. CONCLUSION: The survival time of the gastric cancer patients treated with chemotherapy combined with CIK cells adoptive immunotherapy is significantly longer than that of the patients treated with chemotherapy alone and increasing the frequency of CIK cells adoptive immunotherapy seems to benefit patients more. | Jing-Ting Jiang, Chang-Ping Wu, Lu-Jun Chen, Xiao Zheng, Department of Tumor Biological Treatment, Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China Yi-Bei Zhu, Jing Sun, Xue-Guang Zhang, Key Laboratory of Stem Cell of Jiangsu Province, Institute of Biotechnology, Key Laboratory of Clinical Immunology of Jiangsu Province, Soochow University, Suzhou 215123, Jiangsu Province, China Yue-Ping Shen, Wen-Xiang Wei, Department of Medicine, Soochow University, Suzhou 215123, Jiangsu Province, China Bin-Feng Lu, Department of Immunology, University of Pitts- burgh School of Medicine, Pittsburgh, PA 15261, United States | 2010 | World Journal of Gastroenterology2010，16，48： | 82 |
| 2 | XS0601 REDUCES THE INCIDENCE OF RESTENOSIS: A PROSPECTIVE STUDY OF 335 PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN CHINA显示文摘Background XS0601, consisting of active ingredients (Chuangxiongol and paeoniflorin), has been shown to inhibit arterial neointimal hyperplasia in animal models and in preliminary human studies. The objective of this study was to evaluate the safety and efficacy of XS0601 in preventing restenosis following percutaneous coronary intervention (PCI). Methods A multi-center, randomized, double-blind, placebo-controlled trial was conducted. A total of 335 patients were randomized into treatment with the oral administration of XS0601, or a placebo for 6 months after successful PCI. Angiographic follow-up was scheduled at 6 months, and clinical follow-ups performed at 1, 3 and 6 months after PCI. The primary end point was angiographic restenosis. The secondary end points were the combined incidence of death, target lesion nonfatal myocardial infarction, repeat angioplasty, and coronary artery bypass graft surgery. Results A total of 308 patients (91.9%) completed the study and 145 cases (47.1%) received angiographic follow-up. The restenosis rates were significantly reduced in the XS0601 group as compared with the placebo group (26.0% vs. 47.2%, P < 0.05), and the minimum lumen diameter (MLD) was greater [(2.08 ± 0.89) mm for XS0601 vs. (1.73 ± 0.94) mm for placebo, P < 0.05]. XS0601 also significantly reduced the combined incidence of major adverse cardiac event (10.4% in the XS0601 group vs. 22.7% in the placebo group, P < 0.05). The incidence of recurrent angina at 3 and 6 months after PCI was also significantly reduced in XS0601 group (7.1% and 11.0%) as compared with those in placebo group (19.5% and 42.9%) (P < 0.05). No significant side effects occurred within the 6-month follow-up period in the XS0601 group. Conclusion Administration of XS0601 for 6 months is demonstrated to be safe and effective in reducing restenosis in post-PCI patients. | CHEN Ke-ji SHI Da-zhuo XU Hao LUE Shu-zheng LI Tian-chang KE Yuan-nan ZHANG Min-zhou LU Xiao-yan SUN Rui-yuan YOU Shi-jie | 2006 | Chinese Medical Journal2006，，1： | 83 |
| 3 | Liver cancer incidence and mortality in China: Temporal trends and projections to 2030显示文摘Objective: Liver cancer is one of the most common cancers and major cause of cancer deaths in China,which accounts for over 50% of new cases and deaths worldwide.The systematic liver cancer statistics including of projection through 2030 could provide valuable information for prevention and control strategies in China,and experience for other countries.Methods: The burden of liver cancer in China in 2014 was estimated using 339 cancer registries' data selected from Chinese National Cancer Center(NCC).Incident cases of 22 cancer registries were applied for temporal trends from 2000 to 2014.The burden of liver cancer through 2030 was projected using age-period-cohort model.Results: About 364,800 new cases of liver cancer(268,900 males and 95,900 females) occurred in China,and about 318,800 liver cancer deaths(233,500 males and 85,300 females) in 2014.Western regions of China had the highest incidence and mortality rates.Incidence and mortality rates decreased by about 2.3% and 2.6% per year during the period of 2000-2014,respectively,and would decrease by more than 44% between 2014 and 2030 in China.The young generation,particularly for those aged under 40 years,showed a faster down trend.Conclusions: Based on the analysis,incidence and mortality rates of liver cancer are expected to decrease through 2030,but the burden of liver cancer is still serious in China,especially in rural and western areas.Most cases of liver cancer in China can be prevented through vaccination and more prevention efforts should be focused on high risk groups. | Rongshou Zheng Chunfeng Qu Siwei Zhang Hongmei Zeng Kexin Sun Xiuying Gu Changfa Xia Zhixun Yang He Li Wenqiang Wei Wanqing Chen Jie He | 2018 | Chinese Journal of Cancer Research2018，30，6： | 132 |
| 4 | Antitumor activities of human autologous cytokineinduced killer(CIK)cells against hepatocellular carcinoma cells in vitro and in vivo显示文摘AIM: To characterize the anticancer function of cytokine-induced killer cells (CIK) and develop an adoptiveimmunotherapy for the patients with primary hepatocellularcarcinoma (HCC), we evaluated the proliferation rate,phenotype and the antitumor activity of human CIK cellsfrom healthy donors and HCC patients in vitro and in vivo.METHODS: Peripheral blood mononuclear cells (PBMC) fronhealthy donors and patients with primary HCC were incubatedin vitro and induced into ClK cells in the presence of variouscytokines such as interferon-gamma (IFN-γ), interleukin-1(IL-1), IL-2, and monoclonal antibody (mAb) against CD3.The phenotype and characterization of CIK cells wereidentified by flow cytometric analysis. The cytotoxicity of CIKcells was determined by 51 Cr release assay.RESULTS: The CIK cells were shown to be a heterogeneouspopulation with different cellular phenotypes. Thepercentage of CD3+/CD56+ positive cells, the dominanteffector cells, in total CIK cells from healthy donors andHCC patients, significantly increased from 0.1-0.13 % at day0 to 19.0-20.5 % at day 21 incubation, which suggested thatthe CD3+ CD56+ positive cells proliferated faster than othercell populations of CIK cells in the protocol used in thisstudy. After 28 day in vitro incubation, the ClK cells frompatients with HCC and healthy donors increased by morethan 300-fold and 500-fold in proliferation cell number,respectively. CIK cells originated from HCC patientspossessed a higher in vitro antitumor cytotoxic activity onautologous HCC cells than the autologous lymphokine-activated killer (LAK) cells and PBMC cells. In in vivoanimal experiment, CIK cells had stronger effects on theinhibition of tumor growth in Balb/c nude mice bearing BEL-7402-producing tumor than LAK cells (mean inhibitory rate,84.7 % vs 52.8 %, P < 0.05) or PBMC (mean inhibitoryrate, 84.7% vs37.1%, P<0.01).CONCLUSION: Autologous CIK cells are of highly efficientcytotoxic effector cells against primary hepatocellularcarcinoma cells and might serve as an alternative adoptivetherapeutic strategy for HCC patients. | Fu-Sheng Wang Ming-Xu Liu Bing Zhang Ming Shi Zhou-Yun Lei Wen-Bing Sun Qing-You Du Ju-Mei Chen,Division of Biological Engineering,Beijing Institute of Infectious Diseases,Beijing 100039,China Wen-Bing Sun,Department of Surgery,Beijing Hospital of Infectious Diseases,Beijing 100039,China | 2002 | World Journal of Gastroenterology2002，8，3： | 108 |
| 5 | Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase显示文摘包含 methyltransferase 建筑群的象 3 一样的 methyltransferase (METTL3 ) 催化 N6-methyladenosine (m6A ) 形成,一个新奇 epitranscriptomic 标记;然而,这建筑群的性质仍然保持大部分未知。这里,我们报导人的 m6A methyltransferase 建筑群, Wilm 的肿瘤 1 伙伴蛋白质(WTAP ) 和象 14 一样的 methyltransferase (METTL14 ) 的二个新部件。WTAP 与 METTL3 和 METTL14 交往,并且为他们的本地化被要求进在 vivo 与处理因素的 pre-mRNA 并且为 m6A methyltransferase 的催化活动充实的原子点缀。RNA 的多数在 vivo 由 WTAP 和 METTL3 跳了代表包含一致 m6A 主题的 mRNAs。当 WTAP 不在时, METTL3 的 RNA 有约束力的能力强烈被减少,建议 WTAP 可以工作调整到 mRNA 目标的 m6A methyltransferase 建筑群的招募。而且,在有 photoactivatable-ribonucleoside-enhanced crosslinking 和 immunoprecipitation (同等片断) 的联合的 transcriptomic 分析说明那 WTAP 和 METTL3 调整涉及抄写并且 RNA 处理的基因拼接的表示和选择。在 zebrafish 胚胎的调停 Morpholino 的击倒的指向 WTAP 或 METTL3 引起了织物区别缺点并且增加了 apoptosis。这些调查结果提供 WTAP 可以在 m6A methyltransferase 建筑群作为一个规章的子单元工作并且在 RNA 的 epitranscriptomic 规定起一个关键作用的充分证据新陈代谢。 | Xiao-Li Ping Bao-Fa Sun Lu Wang Wen Xiao Xin Yang Wen-Jia Wang Samir Adhikari Yue Shi Ying Lv Yu-Sheng Chen Xu Zhao Ang Li Ying Yang Ujwal Dahal Xiao-Min Lou Xi Liu Jun Huang Wei-Ping Yuan Xiao-Fan Zhu Tao Cheng Yong-Liang Zhao Xinquan Wang Jannie M Rendtlew Danielsen Feng Liu Yun-Gui Yang | 2014 | Cell Research2014，24，2： | 244 |
| 6 | FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis显示文摘 | Xu Zhao Ying Yang Bao-Fa Sun Yue Shi Xin Yang Wen Xiao Ya-Juan Hao Xiao-Li Ping Yu-Sheng Chen Wen-Jia Wang Kang-Xuan Jin Xing Wang Chun-Min Huang Yu Fu Xiao-Meng Ge Shu-Hui Song Hyun Seok Jeong Hiroyuki Yanagisawa Yamei Niu Gui-Fang Jia Wei Wu Wei-Min Tong Akimitsu Okamoto Chuan He Jannie M Rendtlew Danielsen Xiu-Jie Wang Yun-Gui Yang | 2014 | Cell Research2014，24，12： | 109 |
| 7 | CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes显示文摘染色体编辑工具例如定期聚类短 palindromic 重复(CRISPR ) 联系了的 interspaced 系统(Cas ) 广泛地被用来包括动物接合子和人的房间在模型系统修改基因,并且为基本研究和临床的应用保持巨大的诺言。迄今为止,严肃的知识差距在人的早胚胎,并且在效率和在人的培植前胚胎使用象 CRISPR/Cas9 那样的技术的潜在的离开目标效果留在我们 DNA 修理机制的理解。在这份报告,我们使用了推进的接合子调查 CRISPR/Cas9-mediated 基因在人的房间编辑的 tripronuclear (3PN ) 。我们发现 CRISPR/Cas9 能有效地劈开内长的 -globin 基因(HBB ) 。然而,相应再结合的效率指导了 HBB 的修理(HDR ) 是低的,编辑胚胎是马赛克。离开目标劈开在由 T7E1 试金并且 whole-exome 定序揭示了的这些 3PN 接合子也是明显的。而且,内长的 delta-globin 基因(HBD ) 对 HBB 相应,与外长的施主 oligos 竞争了充当修理模板,导致倔强的变化。我们的数据也显示在这些胚胎的 HBB 地点的修理通过非转线路 HDR 小径优先地发生了。一起拿,我们的工作加亮紧迫的需要进一步改进 CRISPR/Cas9 平台的忠实和特性,为编辑的 CRSIPR/Cas9-mediated 的任何临床的应用程序的一个前提。 | Puping Liang Yanwen Xu Xiya Zhang Chenhui Ding Rui Huang Zhen Zhang Jie Lv Xiaowei Xie Yuxi Chen Yujing Li Ying Sun Yaofu Bai Zhou Songyang Wenbin Ma Canquan Zhou Junjiu Huang | 2015 | Protein & Cell2015，6，5： | 149 |
| 8 | Cytoplasmic m6A reader YTHDF3 promotes mRNA translation显示文摘 | Ang Li Yu-Sheng Chen Xiao-Li Ping Xin Yang Wen Xiao Ying Yang Hui-Ying Sun Qin Zhu Poonam Baidya Xing Wang Devi Prasad Bhattarai Yong-Liang Zhao Bao-Fa Sun Yun-Gui Yang | 2017 | Cell Research2017，27，3： | 82 |
| 9 | Cancer incidence and mortality in China, 2014显示文摘Background: National Central Cancer Registry of China(NCCRC) updated nationwide cancer statistics using population-based cancer registry data in 2014 collected from all available cancer registries.Methods: In 2017, 449 cancer registries submitted cancer registry data in 2014, among which 339 registries' data met the criteria of quality control and were included in analysis. These cancer registries covered 288,243,347 population, accounting for about 21.07% of the national population in 2014. Numbers of nationwide new cancer cases and deaths were estimated using calculated incidence and mortality rates and corresponding national population stratified by area, sex, age group and cancer type. The world Segi's population was applied for agestandardized rates.Results: A total of 3,804,000 new cancer cases were diagnosed, the crude incidence rate was 278.07/100,000(301.67/100,000 in males, 253.29/100,000 in females) and the age-standardized incidence rate by world standard population(ASIRW) was 186.53/100,000. Calculated age-standardized incidence rate was higher in urban areas than in rural areas(191.6/100,000 vs. 179.2/100,000). South China had the highest cancer incidence rate while Southwest China had the lowest incidence rate. Cancer incidence rate was higher in female for population between20 to 54 years but was higher in male for population younger than 20 years or over 54 years. A total of 2,296,000 cancer deaths were reported, the crude mortality rate was 167.89/100,000(207.24/100,000 in males,126.54/100,000 in females) and the age-standardized mortality rate by world standard population(ASMRW) was106.09/100,000. Calculated age-standardized mortality rate was higher in rural areas than in urban areas(110.3/100,000 vs. 102.5/100,000). East China had the highest cancer mortality rate while North China had the lowest mortality rate. The mortality rate in male was higher than that in female. Common cancer types and major causes of cancer death differed between age group and sex.Conclusions: Heavy cancer burden and its disparities between area, sex and age group pose a major challenge to public health in China. Nationwide cancer registry plays a crucial role in cancer prevention and control. | Wanqing Chen Kexin Sun Rongshou Zheng Hongmei Zeng Siwei Zhang Changfa Xia Zhixun Yang He Li Xiaonong Zou Jie He | 2018 | Chinese Journal of Cancer Research2018，30，1： | 832 |
| 10 | Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression显示文摘Recently,increasing evidence has suggested the association between gut dysbiosis and Alzheimer's disease(AD)progression,yet the role of gut microbiota in AD pathogenesis remains obscure.Herein,we provide a potential mechanistic link between gut microbiota dysbiosis and neuroinflammation in AD progression.Using AD mouse models,we discovered that,during AD progression,the alteration of gut microbiota composition leads to the peripheral accumulation of phenylalanine and isoleucine,which stimulates the differentiation and proliferation of pro-inflammatory T helper 1(Thl)cells.The brain-infiltrated peripheral Th1 immune cells are associated with the Ml microglia aaivation,contributing to AD-associated neuroinflammation.Importantly,the elevation of phenylalanine and isoleucine concentrations and the increase of Th1 cell frequency in the blood were also observed in two small independent cohorts of patients with mild cognitive impairment(MCI)due to AD.Furthermore,GV-971,a sodium oligomannate that has demonstrated solid and consistent cognition improvement in a phase 3 clinical trial in China,suppresses gut dysbiosis and the associated phenylalanine/isoleucine accumulation,harnesses neuroinflammation and reverses the cognition impairment.Together,our findings highlight the role of gut dysbiosis-promoted neuroinflammation in AD progression and suggest a novel strategy for AD therapy by remodelling the gut microbiota. | Xinyi Wang Guangqiang Sun Teng Feng Jing Zhang Xun Huang Tao Wang Zuoquan Xie Xingkun Chu Jun Yang Huan Wang Shuaishuai Chang Yanxue Gong Lingfei Ruan Guanqun Zhang Siyuan Yan Wen Lian Chen Du Dabing Yang Qingli Zhang Feifei Lin Jia Liu Haiyan Zhang Changrong Ge Shifu Xiao Jian Ding Meiyu Geng | 2019 | Cell Research2019，29，10： | 192 |
| 11 | Future Physics Programme of BESⅢ显示文摘There has recently been a dramatic renewal of interest in hadron spectroscopy and charm physics. This renaissance has been driven in part by the discovery of a plethora of charmonium-like XYZ states at BESⅢ and B factories, and the observation of an intriguing proton-antiproton threshold enhancement and the possibly related X(1835) meson state at BESⅢ, as well as the threshold measurements of charm mesons and charm baryons. We present a detailed survey of the important topics in tau-charm physics and hadron physics that can be further explored at BESⅢ during the remaining operation period of BEPCⅡ. This survey will help in the optimization of the data-taking plan over the coming years, and provides physics motivation for the possible upgrade of BEPCⅡ to higher luminosity. | M.Ablikim M.N.Achasov P.Adlarson S.Ahmed M.Albrecht M.Alekseev A.Amoroso F.F.An Q.An Y.Bai O.Bakina R.Baldini Ferroli Y.Ban K.Begzsuren J.V.Bennett N.Berger M.Bertani D.Bettoni F.Bianchi J Biernat J.Bloms I.Boyko R.A.Briere L.Calibbi H.Cai X.Cai A.Calcaterra G.F.Cao N.Cao S.A.Cetin J.Chai J.F.Chang W.L.Chang J.Charles G.Chelkov Chen G.Chen H.S.Chen J.C.Chen M.L.Chen S.J.Chen Y.B.Chen H.Y.Cheng W.Cheng G.Cibinetto F.Cossio X.F.Cui H.L.Dai J.P.Dai X.C.Dai A.Dbeyssi D.Dedovich Z.Y.Deng A.Denig Denysenko M.Destefanis S.Descotes-Genon F.De Mori Y.Ding C.Dong J.Dong L.Y.Dong M.Y.Dong Z.L.Dou S.X.Du S.I.Eidelman J.Z.Fan J.Fang S.S.Fang Y.Fang R.Farinelli L.Fava F.Feldbauer G.Felici C.Q.Feng M.Fritsch C.D.Fu Y.Fu Q.Gao X.L.Gao Y.Gao Y.Gao Y.G.Gao Z.Gao B.Garillon I.Garzia E.M.Gersabeck A.Gilman K.Goetzen L.Gong W.X.Gong W.Gradl M.Greco L.M.Gu M.H.Gu Y.T.Gu A.Q.Guo F.K.Guo L.B.Guo R.P.Guo Y.P.Guo A.Guskov S.Han X.Q.Hao F.A.Harris K.L.He F.H.Heinsius T.Held Y.K.Heng Y.R.Hou Z.L.Hou H.M.Hu J.F.Hu T.Hu Y.Hu G.S.Huang J.S.Huang X.T.Huang X.Z.Huang Z.L.Huang N.Huesken T.Hussain W.Ikegami Andersson W.Imoehl M.Irshad Q.Ji Q.P.Ji X.B.Ji X.L.Ji H.L.Jiang X.S.Jiang X.Y.Jiang J.B.Jiao Z.Jiao D.P.Jin S.Jin Y.Jin T.Johansson N.Kalantar-Nayestanaki X.S.Kang R.Kappert M.Kavatsyuk B.C.Ke I.K.Keshk T.Khan A.Khoukaz P.Kiese R.Kiuchi R.Kliemt L.Koch O.B.Kolcu B.Kopf M.Kuemmel M.Kuessner A.Kupsc M.Kurth M.G.Kurth W.Kuhn J.S.Lange P.Larin L.Lavezzi H.Leithoff T.Lenz C.Li Cheng Li D.M.Li F.Li F.Y.Li G.Li H.B.Li H.J.Li J.C.Li J.W.Li Ke Li L.K.Li Lei Li P.L.Li P.R.Li Q.Y.Li W.D.Li W.G.Li X.H.Li X.L.Li X.N.Li X.Q.Li Z.B.Li H.Liang H.Liang Y.F.Liang Y.T.Liang G.R.Liao L.Z.Liao J.Libby C.X.Lin D.X.Lin Y.J.Lin B.Liu B.J.Liu C.X.Liu D.Liu D.Y.Liu F.H.Liu Fang Liu Feng Liu H.B.Liu H.M.Liu Huanhuan Liu Huihui Liu J.B.Liu J.Y.Liu K.Y.Liu Ke Liu Q.Liu S.B.Liu T.Liu X.Liu X.Y.Liu Y.B.Liu Z.A.Liu Zhiqing Liu Y.F.Long X.C.Lou H.J.Lu J.D.Lu J.G.Lu Y.Lu Y.P.Lu C.L.Luo M.X.Luo P.W.Luo T.Luo X.L.Luo S.Lusso X.R.Lyu F.C.Ma H.L.Ma L.L.Ma M.M.Ma Q.M.Ma X.N.Ma X.X.Ma X.Y.Ma Y.M.Ma F.E.Maas M.Maggiora S.Maldaner S.Malde Q.A.Malik A.Mangoni Y.J.Mao Z.P.Mao S.Marcello Z.X.Meng J.G.Messchendorp G.Mezzadri J.Min T.J.Min R.E.Mitchell X.H.Mo Y.J.Mo C.Morales Morales N.Yu.Muchnoi H.Muramatsu A.Mustafa S.Nakhoul Y.Nefedov F.Nerling I.B.Nikolaev Z.Ning S.Nisar S.L.Niu S.L.Olsen Q.Ouyang S.Pacetti Y.Pan M.Papenbrock P.Patteri M.Pelizaeus H.P.Peng K.Peters A.A.Petrov J.Pettersson J.L.Ping R.G.Ping A.Pitka R.Poling V.Prasad M.Qi T.Y.Qi S.Qian C.F.Qiao N.Qin X.P.Qin X.S.Qin Z.H.Qin J.F.Qiu S.Q.Qu K.H.Rashid C.F.Redmer M.Richter M.Ripka A.Rivetti V.Rodin M.Rolo G.Rong J.L.Rosner Ch.Rosner M.Rump A.Sarantsev M.Savrie K.Schoenning W.Shan X.Y.Shan M.Shao C.P.Shen P.X.Shen X.Y.Shen H.Y.Sheng X.Shi X.D Shi J.J.Song Q.Q.Song X.Y.Song S.Sosio C.Sowa S.Spataro F.F.Sui G.X.Sun J.F.Sun L.Sun S.S.Sun X.H.Sun Y.J.Sun Y.K Sun Y.Z.Sun Z.J.Sun Z.T.Sun Y.T Tan C.J.Tang G.Y.Tang X.Tang V.Thoren B.Tsednee I.Uman B.Wang B.L.Wang C.W.Wang D.Y.Wang H.H.Wang K.Wang L.L.Wang L.S.Wang M.Wang M.Z.Wang Wang Meng P.L.Wang R.M.Wang W.P.Wang X.Wang X.F.Wang X.L.Wang Y.Wang Y.F.Wang Z.Wang Z.G.Wang Z.Y.Wang Zongyuan Wang T.Weber D.H.Wei P.Weidenkaff H.W.Wen S.P.Wen U.Wiedner G.Wilkinson M.Wolke L.H.Wu L.J.Wu Z.Wu L.Xia Y.Xia S.Y.Xiao Y.J.Xiao Z.J.Xiao Y.G.Xie Y.H.Xie T.Y.Xing X.A.Xiong Q.L.Xiu G.F.Xu L.Xu Q.J.Xu W.Xu X.P.Xu F.Yan L.Yan W.B.Yan W.C.Yan Y.H.Yan H.J.Yang H.X.Yang L.Yang R.X.Yang S.L.Yang Y.H.Yang Y.X.Yang Yifan Yang Z.Q.Yang M.Ye M.H.Ye J.H.Yin Z.Y.You B.X.Yu C.X.Yu J.S.Yu C.Z.Yuan X.Q.Yuan Y.Yuan A.Yuncu A.A.Zafar Y.Zeng B.X.Zhang B.Y.Zhang C.C.Zhang D.H.Zhang H.H.Zhang H.Y.Zhang J.Zhang J.L.Zhang J.Q.Zhang J.W.Zhang J.Y.Zhang J.Z.Zhang K.Zhang L.Zhang S.F.Zhang T.J.Zhang X.Y.Zhang Y.Zhang Y.H.Zhang Y.T.Zhang Yang Zhang Yao Zhang Yi Zhang Yu Zhang Z.H.Zhang Z.P.Zhang Z.Q.Zhang Z.Y.Zhang G.Zhao J.W.Zhao J.Y.Zhao J.Z.Zhao Lei Zhao Ling Zhao M.G.Zhao Q.Zhao S.J.Zhao T.C.Zhao Y.B.Zhao Z.G.Zhao A.Zhemchugov B.Zheng J.P.Zheng Y.Zheng Y.H.Zheng B.Zhong L.Zhou L.P.Zhou Q.Zhou X.Zhou X.K.Zhou Xingyu Zhou Xiaoyu Zhou Xu Zhou A.N.Zhu J.Zhu J.Zhu K.Zhu K.J.Zhu S.H.Zhu W.J.Zhu X.L.Zhu Y.C.Zhu Y.S.Zhu Z.A.Zhu J.Zhuang B.S.Zou J.H.Zou 无 | 2020 | Chinese Physics C2020，44，4： | 517 |
| 12 | Prevalence of Autism Spectrum Disorder in China:A Nationwide Multi-center Population-based Study Among Children Aged 6 to 12 Years显示文摘This study aimed to obtain the first national estimate of the prevalence of autism spectrum disorder(ASD) in Chinese children.We targeted the population of 6 to 12-year-old children for this prevalence study by multistage convenient cluster sampling.The Modified Chinese Autism Spectrum Rating Scale was used for the screening process.Of the target population of 142,086 children,88.5%(n=125,806) participated in the study.A total of 363 children were confirmed as having ASD.The observed ASD prevalence rate was 0.29%(95% CI:0.26%-0.32%) for the overall population.After adjustment for response rates,the estimated number of ASD cases was867 in the target population sample,thereby achieving an estimated prevalence of 0.70%(95% CI:0.64%-0.74%).The prevalence was significantly higher in boys than in girls(0.95%;95% CI:0.87%-1.02% versus 0.30%;95%CI:0.26%-0.34%;P <0.001).Of the 363 confirmed ASD cases,43.3% were newly diagnosed,and most of those(90.4%) were attending regular schools,and 68.8% of the children with ASD had at least one neuropsychiatric comorbidity.Our findings provide reliable data on the estimated ASD prevalence and comorbidities in Chinese children. | Hao Zhou Xiu Xu Weili Yan Xiaobing Zou Lijie Wu Xuerong Luo Tingyu Li Yi Huang Hongyan Guan Xiang Chen Meng Mao Kun Xia Lan Zhang Erzhen Li Xiaoling Ge Lili Zhang Chunpei Li Xudong Zhang Yuanfeng Zhou Ding Ding Andy Shih Eric Fombonne Yi Zheng Jisheng Han Zhongsheng Sun Yong-hui Jiang Yi Wang LATENT-NHC Study Team | 2020 | Neuroscience Bulletin2020，36，9： | 158 |
| 13 | Cancer burden of major cancers in China:A need for sustainable actions显示文摘Cancer is still a major health problem in China although numerous efforts have been made for its prevention and control.Findings from this study showed that lung cancer remains the most common type of cancer diagnosed,and was attributed to nearly 30%of all cancer-related deaths.The incidence of the five most common cancers,in China,in 2015,including cancers of the lungs,stomach,colorectum,liver and breast,accounted for almost 60%of all cancers diagnosed.The high cancer burden in China highlights the need for further improvement in health education,professional training and the building up an anti-cancer network for introducing and implementing sustainable actions for cancer control. | Maomao Cao He Li Dianqin Sun Wanqing Chen | 2020 | Cancer Communications2020，40，5： | 140 |
| 14 | Cancer statistics in China and United States,2022:profiles,trends,and determinants显示文摘Background:The cancer burden in the United States of America(USA)has decreased gradually.However,China is experiencing a transition in its cancer profiles,with greater incidence of cancers that were previously more common in the USA.This study compared the latest cancer profiles,trends,and determinants between China and USA.Methods:This was a comparative study using open-source data.Cancer cases and deaths in 2022 were calculated using cancer estimates from GLOBOCAN 2020 and population estimates from the United Nations.Trends in cancer incidence and mortality rates in the USA used data from the Surveillance,Epidemiology,and End Results program and National Center for Health Statistics.Chinese data were obtained from cancer registry reports.Data from the Global Burden of Disease 2019 and a decomposition method were used to express cancer deaths as the product of four determinant factors.Results:In 2022,there will be approximately 4,820,000 and 2,370,000 new cancer cases,and 3,210,000 and 640,000 cancer deaths in China and the USA,respectively.The most common cancers are lung cancer in China and breast cancer in the USA,and lung cancer is the leading cause of cancer death in both.Age-standardized incidence and mortality rates for lung cancer and colorectal cancer in the USA have decreased significantly recently,but rates of liver cancer have increased slightly.Rates of stomach,liver,and esophageal cancer decreased gradually in China,but rates have increased for colorectal cancer in the whole population,prostate cancer in men,and other seven cancer types in women.Increases in adult population size and population aging were major determinants for incremental cancer deaths,and case-fatality rates contributed to reduced cancer deaths in both countries.Conclusions:The decreasing cancer burden in liver,stomach,and esophagus,and increasing burden in lung,colorectum,breast,and prostate,mean that cancer profiles in China and the USA are converging.Population aging is a growing determinant of incremental cancer burden.Progress in cancer prevention and care in the USA,and measures to actively respond to population aging,may help China to reduce the cancer burden. | Changfa Xia Xuesi Dong He Li Maomao Cao Dianqin Sun Siyi He Fan Yang Xinxin Yan Shaoli Zhang Ni Li Wanqing Chen | 2022 | Chinese Medical Journal2022，，5： | 827 |
| 15 | Strongly peraluminous granites of Mesozoic in Eastern Nanling Range, southern China: Petrogenesis and implications for tectonics显示文摘The strongly peraluminous granites (SPGs) of Eastern Nanling Range (ENR) are a characteristic of all bearing highly aluminous minerals, such as muscovite±Al-rich biotite±tourmaline±garnet, and lack of cordierite. In respect of petrography, geochemistry, Nd isotope, and single grain zircon U-Pb dating, the representative granite bodies of them are studied. The research shows that these granites were emplaced in two stages, namely 228-225 Ma BP and J2-3 159-156 Ma BP, belonging to Indosinian and early Yanshanian periods, respectively, and they have low εNd(t) values (-10.6--11.1), high A/CNK, Rb/Sr ratios and tDM values (1887-1817 Ma), and REE's tetrad effect (TE1, 3=1.13-1.34). In comparison with related geology, petrology and chronology of granites in adjacent regions, it is suggested that Indosinian SPGs of ENR formed in the circumstance of post-collisional extension 20 Ma after the major collision of Indosinian Movement (258-243 Ma BP) in Indo-China Peninsula, and early Yanshanian SPGs formed in the background of back-arc extension setting controlled by paleo-Pacific tectonic domain, and J1, the interval of two stages, is the interim from Tethyan to Pacific tectonic domains in South China. These SPGs have similar geological and geochemical characteristics, because they all crystallized from the magma of partial melting of early Proterozoic metasedimentary rocks when the thickened crust (≤50 km) became thinning, decompression, and transmitting of water. | SUN Tao, ZHOU Xinmin, CHEN Peirong, LI Huimin, ZHOU Hongying, WANG Zhicheng & SHEN Weizhou Department of Earth Sciences, Nanjing University, Nanjing 210093, China Tianjin Institute of Geology and Mineral Resources, China Geological Survey, Tianjin 300170, China | 2005 | Science China Earth Sciences2005，48，2： | 78 |
| 16 | Discovery of ultrahigh-pressure magnesite-bearing garnet lherzolite (>3.8 GPa) in the Altyn Tagh, Northwest China显示文摘Magnesite-bearing garnet Iherzolite from the Altyn Tagh, associated with garnet pyroxenite, and garnet-bearing felsic gneiss, crops out as lenses in Proterozoic gneiss about 100 km east of the Jianggelasayi River. The garnet Iherzolite, together with the eclogite in western Jianggelasayi, composes a high-pressure to ultrahigh-pressure metamorphic belt in the southern margin of the Altyn Tagh. Parageneses of minerals from magnesite-bearing garnet Iherzolite indicate that the rock evolved a multi-stage metamorphism. The peak-stage metamorphism produces an assemblage of Grt+Ol+Opx+Cpx±Mgs, in which A12O3 content of Opxis very low (0.30-0.66wt%). The calculated P-T condition of the peak stage is 3.8-5.lGPa and 880-970°C, some exsolution rods of clinopyroxene and rutile occur in the Grt and magnesite is rimed by dolomite and orthopyroxene, all implying that the peak stage was a UHP metamorphic process. Together with regional geological studies, isotopic dating and the discovery of coesite inclusions in | LIU Liang, SUN Yong, XIAO Peixi, CHE Zicheng, LUO Jinhai, CHEN Danling, WANG Yan, ZHANG Anda, CHEN Liang & WANG YongheKey Laboratory of Continental Dynamics of the Ministry of Education, Northwest University, Xi’an 710069, China The Northwest Institute of | 2002 | Chinese Science Bulletin2002，47，11： | 69 |
| 17 | RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings显示文摘在有前列腺癌症的不同赛跑的病人之中有显著不同;然而,位于这差别下面的机制仍然保持不清楚。这里,我们在场 transcriptome 的一处全面风景用 RNA-seq,越过关于基因熔化的前列腺癌症 transcriptomes 的揭示巨大的差异,长 noncoding RNA (长 ncRNA ) ,其他的拼接和体的变化从中国人口 14 主要前列腺癌症和他们的配对的正常对应物介绍。14 个肿瘤(21.4%) 中的三个在中国病人怀有 TMPRSS2 尔格熔化,和这熔化的低流行进一步在一个另外的肿瘤集合(10/54=18.5%) 被证实。尤其是,二新奇基因熔化, CTAGE5-KHDRBS3 (20/54=37%) 和 USP9Y-TTTY15 (19/54=35.2%) ,在我们的耐心的队经常发生了。介绍的进一步系统的 transcriptional 识别了是在肿瘤表示的差别的众多的长 ncRNAs。在长 ncRNA 和基因的表示之间的关联的分析建议长 ncRNAs 可以在 transcriptional 规定以外有功能。这研究在中国人口产出新卓见进前列腺癌症的致病。 | Shancheng Ren Zhiyu Peng Jian-Hua Mao Yongwei Yu Changjun Yin Xin Gao Zilian Cui Jibin Zhang Kang Yi Weidong Xu Chao Chen Fubo Wang Xinwu Guo Ji Lu Jun Yang Min Wei Zhijian Tian Yinghui Guan Liang Tang Chuanliang Xu Linhui Wang Xu Gao Wei Tian Jian Wang Huanming Yang Jun Wang Yinghao Sun | 2012 | Cell Research2012，22，5： | 66 |
| 18 | Current pattern of Chinese dialysis units: a cohort study in a representative sample of units显示文摘 | ZHOU Qiu-gen JIANG Jian-ping WU Sheng-jie TIAN Jian-wei CHEN Jiang-hua YU Xue-qing CHEN Ping-yan MEI Chang-lin XIONG Fei SHI Wei ZHOU Wei LIU Xu-sheng SUN Shi-ren XIE Di LIU Jun XU Xin HOU Fan-fan | 2012 | Chinese Medical Journal2012，，19： | 69 |
| 19 | NK cell-based immunotherapy for malignant diseases显示文摘生来的杀手(NK ) 房间对癌症在主人免疫起关键作用。在反应,癌症开发机制逃离 NK 房间攻击或导致有缺点的 NK 房间。当前的 NK 基于房间的癌症免疫疗法试图用几条途径克服 NK 房间麻痹。一条途径使用扩展 allogeneic NK 房间,它没被象自体同源的 NK 房间一样的自我 histocompatibility 抗原禁止,为采纳细胞的免疫疗法。另一条采纳转移途径使用稳定的 allogeneic NK 房间线,它为质量控制和大规模生产是更实际的。第三条途径是新鲜 NK 房间或 NK 房间线的基因修正高度表示 cytokines, Fc 受体或妄想的肿瘤抗原受体。治疗学的 NK 细胞能从各种各样的来源被导出,包括细胞,干细胞或甚至导致的 pluripotent 干细胞( iPSCs ),和许多激发器能被用于的外设或绳索血在实验室或好生产实践( GMP )的大规模生产设备包括可溶的生长因素,使不能调动的分子或抗体,和另外的细胞的使活跃之物。到在临床的试用的癌症的对待几类型的 NK 房间治疗的一张表这里被考察。基于 NK 的免疫疗法的几条不同途径例如织物特定的 NK 房间,漂亮面向受体的 NK 房间和化学上对待的 NK 房间,被讨论。一些新技术或策略到由非侵略的成像的监视器 NK 房间治疗,预定 NK 房间治疗由的效率在 vivo 实验并且在临床的试用评估 NK 房间治疗途径也被介绍。 | Min Cheng Yongyan Chen Weihua Xiao Rui Sun Zhigang Tian | 2013 | Cellular & Molecular Immunology2013，10，3： | 61 |
| 20 | Incidence and mortality of colorectal cancer in China, 2011显示文摘Objective: Colorectal cancer is the third most common type of cancer and the fourth leading cause of cancer-related death in the world. This article provides the most up-to-date overview of colorectal cancer burden in China.Methods: Totally 234 cancer registries submitted data of 2011 to the National Central Cancer Registry(NCCR). Qualified data from 177 registries was pooled and analyzed. The crude incidence and mortality rates of colorectal cancer were calculated by age, gender and geographic area. The numbers of new cases and deaths were estimated using the 5-year age-specific cancer incidence/mortality rates and the corresponding populations. China census in 2000 and Segi's world population were applied for age standardized rates.Results: The estimate of new cases diagnosed with colorectal cancer of China in 2011 was 310,244(178,404 for males and 131,840 for females, 195,117 in urban areas and 115,128 in rural areas), accounting for 9.20% of overall new cancer cases. The crude incidence of colorectal cancer ranked fourth in all cancer sites with rate of 23.03/100,000(25.83/100,000 for males and 20.08/100,000 for female, 28.25/100,000 in urban areas and 17.54/100,000 in rural areas). The age-standardized rates by China population and by World population were 16.79/100,000 and 16.52/100,000, respectively. The estimated number of colorectal cancer deaths of China in 2011 was 149,722(86,427 for males and 63,295 for females, 91,682 in urban areas and 58,040 in rural areas), accounting for 7.09% of overall cancer deaths. The crude mortality rate for colorectal cancer ranked fifth leading cause of cancer-related death in all cancer sites with rate of 11.11/100,000(12.51/100,000 for males and 9.64/100,000 for female, 13.27/100,000 in urban areas and 8.84/100,000 in rural areas). The age-standardized rates by China population and by World population for mortality were 7.77/100,000 and 7.66/100,000, respectively. For both of incidence and mortality, the rates of colorectal cancer were much higher in males than in females, and in rural areas than in urban areas. The rate of colorectal cancer increased greatly with age, especially after 40 or 45 years old.Conclusions: Colorectal cancer is a relative common cancer in China, especially for males in urban areas. Targeted prevention and early detection programs should be carried out. | Shuzheng Liu Rongshou Zheng Meng Zhang Siwei Zhang Xibin Sun Wanqing Chen | 2015 | Chinese Journal of Cancer Research2015，27，1： | 78 |
您所在的机构暂未开通此部分的功能，请联系管理员